Abstract 534P
Background
Lung cancer is a major health concern worldwide. It is the leading cause of cancer-related deaths among both men and women. The current study aims to investigate the role of desmocollin 2 (DSC2) protein in the proliferation, migration, drug resistance and immunotherapy of lung cancer cells. Lung cancer is a major health concern worldwide.
Methods
To examine the role of DSC2 in lung cancer cells, various assays were performed, including CCK-8 and colony formation assays to assess the impact on cell viability and colony formation, respectively. Transwell and wound-healing assays were also conducted to evaluate the impact on cell migration. The flow cytometry double staining assay was employed to detect the apoptosis rate of cells with DSC2 added with cisplatin. Western blotting analysis was used to examine the levels of cell cycle, PI3k/Akt, and apoptosis-related proteins.
Results
The results of this study revealed that DSC2 is upregulated in clinical lung cancer tissues compared to pericarcinomatous tissues and differentially expressed in lung cancer cell lines. The down-regulation of DSC2 in A549 and H358 lung cancer cells significantly reduced cell proliferation, metastasis, and motility. In addition to lung adenocarcinoma cell lines, we also examined its expression in lung squamous cell lines, such as H226. However, the overexpression of DSC2 in H23 and PC9 cell lines showed opposite effects. Western blotting showed that DSC2 could reduce the level of phosphorylated Akt (Ser 473) and p-mTOR. Thus, the study suggested that DSC2 up-regulation promotes proliferation and invasiveness through activation of the PI3K/AKT pathway. DSC2 knockdown can significantly decrease the levels of cyclinB and wee1 protein in A549 and H226. Cisplatin combined with DSC2 knockdown can enhance cell apoptosis rates.
Conclusions
These data suggest that dsc2 promotes the proliferation and migration of lung cancer cells in vitro. Also, the results suggested that dsc2 could affect the cell cycle and apoptosis of lung cells. Furthermore, knockdown of dsc2 could sensitize cisplatin in both lung adenocarcinoma and lung squamous cell lines. Thus, we suggested that dsc2 can be used as a therapeutic target for lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Affiliated Hangzhou First People’s Hospital of Zhejiang university.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract